What does this research mean for the field?

Prior treatment exposure before transarterial radioembolization (TARE) negatively impacts progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC), with those receiving TARE as initial treatment showing better outcomes. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 21, 2026Journal of Hepatocellular CarcinomaOpen Access

Post-TARE Survival Outcomes in Hepatocellular Carcinoma: Influence of Pre-TARE Immunotherapy and Targeted Therapy in a Real-World Cohort

View Full Paper

Ask AI

Bookmark

This study aims to determine how prior treatments affect survival outcomes in hepatocellular carcinoma (HCC) patients after transarterial radioembolization (TARE).
Retrospective analysis of 71 patients with HCC treated with TARE.
Patients categorized into two groups: prior systemic therapy and initial TARE.
Assessment of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).
Cox regression analyses to identify prognostic factors, including baseline neutrophil-to-lymphocyte ratio (NLR).
Group undergoing initial TARE had a higher ORR (87.5%) compared to prior systemic therapy group (56.4%, P = 0.004).
Median PFS was longer in the initial TARE group (17.45 months) than in the prior therapy group (4.86 months; P = 0.023).
No significant difference in OS was noted between groups.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis evaluates survival outcomes in HCC linked to treatment prior to TARE, suggesting implications for patient management.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69994b41873532290d01f63a https://doi.org/10.2147/jhc.s567355

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis evaluates survival outcomes in HCC linked to treatment prior to TARE, suggesting implications for patient management.

Post-TARE Survival Outcomes in Hepatocellular Carcinoma: Influence of Pre-TARE Immunotherapy and Targeted Therapy in a Real-World Cohort

Key Points

Discussion

Implication

Cite This Study

Post-TARE Survival Outcomes in Hepatocellular Carcinoma: Influence of Pre-TARE Immunotherapy and Targeted Therapy in a Real-World Cohort

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider